RxDoctor Payments Data

Jing Zhang, MD

Family Medicine · Cary, NCNPI 1245277847

Payments from drug & device makers

$22,584in general payments, 2019–2025

Across 1,345 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$3K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • plus $10K from 45 others

What the payments were for

  • Speaking & faculty fees$250%
  • Food & beverage$22,36199%
  • Education$1981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,584 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$89,096
Medicare patients
190
Services billed
1,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$132,309
JardianceEmpagliflozin46$57,273
Synjardy XrEmpagliflozin/Metformin Hcl48$48,998
FarxigaDapagliflozin Propanediol49$43,611
Xigduo XrDapaglifloz Propaned/Metformin37$43,305
MounjaroTirzepatide19$21,799
Breo ElliptaFluticasone/Vilanterol22$21,087
Janumet XrSitagliptin Phos/Metformin Hcl22$18,835
MyrbetriqMirabegron23$13,314
VascepaIcosapent Ethyl12$10,105
LinzessLinaclotide11$6,844
SynthroidLevothyroxine Sodium61$5,871
Rosuvastatin Calcium337$4,329
Levothyroxine Sodium299$4,304
PaxlovidNirmatrelvir/Ritonavir29$4,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,831$132,30972 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,170$106,27194 claims
AstraZenecaFarxiga$2,721$43,61149 claims
GSKBreo Ellipta, Shingrix$404$25,28441 claims
Lilly USA, LLCMounjaro$1,579$21,79919 claims
MerckJanumet Xr$384$18,83522 claims
Astellas Pharma US IncMyrbetriq$431$13,31423 claims
AbbVieLinzess, Synthroid$2,385$12,71572 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$169$4,304299 claims
PfizerPaxlovid$941$4,28829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →